Trovagene and Barretos Cancer Hospital to vealuate urine-based HPV assay

theflyonthewall.com

Trovagene and the PIO XII Foundation, affiliated with Brazil's Barretos Cancer Hospital, announced that they entered into a research collaboration to evaluate the performance of a urine-based molecular assay for detection of HPV types associated with cervical lesions. The goal of the study is to determine whether this assay can potentially replace Pap smears as the primary screen for cervical cancer risk in Brazil's healthcare system. Barretos Cancer Hospital, Brazil's preeminent center for oncology research and cancer treatment, will conduct the study using Trovagene's proprietary, urine-based method for determining the presence of high risk HPV types, allowing for completely non-invasive HPV carrier screening.

Rates

View Comments (0)